BACKGROUND: Two major problems for translating gene therapy for heart failure therapy are: safe and efficient delivery and the inability to establish a relationship between vector exposure and in vivo effects. We present a pharmacokinetics (PK) analysis of molecular cardiac surgery with recirculating delivery (MCARD) of scAAV6-βARKct. MCARD's stable cardiac specific delivery profile was exploited to determine vector exposure, half-life, and systemic clearance. METHODS AND RESULTS: Five naive sheep underwent MCARD with 10(14) genome copies of scAAV6-βARKct. Blood samples were collected over the recirculation interval time of 20 minutes and evaluated with quantitative polymerase chain reaction (qPCR). C(t) curves were generated and expressed on a log scale. The exposure, half-life, and clearance curves were generated for analysis. qPCR and Western blots were used to determine biodistribution. Finally, all in vivo transduction data was plotted against MCARD's PK to determine if a relationship existed. Vector concentrations at each time point were (cardiac and systemic, respectively): 5 minutes: 9.16 ± 0.15 and 3.21 ± 0.38; 10 minutes: 8.81 ± 0.19 and 3.62 ± 0.37; 15 minutes: 8.75 ± 0.12 and 3.69 ± 0.31; and 20 minutes: 8.66 ± 0.22 and 3.95 ± 0.26; P < .00001. The half life of the vector was 2.66 ± 0.24 minutes. PK model data revealed that only 0.61 ± 0.43% of the original dose remained in the blood after delivery, and complete clearance from the system was achieved at 1 week. A PK transfer function revealed a positive correlation between exposure and in vivo transduction. Robust βARKct expression was found in all cardiac regions with none in the liver. CONCLUSION: MCARD may offer a viable method to establish a relationship between vector exposure and in vivo transduction. Using this methodology, it may be possible to address a critical need for establishing an effective therapeutic window. Published by Elsevier Inc.
BACKGROUND: Two major problems for translating gene therapy for heart failure therapy are: safe and efficient delivery and the inability to establish a relationship between vector exposure and in vivo effects. We present a pharmacokinetics (PK) analysis of molecular cardiac surgery with recirculating delivery (MCARD) of scAAV6-βARKct. MCARD's stable cardiac specific delivery profile was exploited to determine vector exposure, half-life, and systemic clearance. METHODS AND RESULTS: Five naive sheep underwent MCARD with 10(14) genome copies of scAAV6-βARKct. Blood samples were collected over the recirculation interval time of 20 minutes and evaluated with quantitative polymerase chain reaction (qPCR). C(t) curves were generated and expressed on a log scale. The exposure, half-life, and clearance curves were generated for analysis. qPCR and Western blots were used to determine biodistribution. Finally, all in vivo transduction data was plotted against MCARD's PK to determine if a relationship existed. Vector concentrations at each time point were (cardiac and systemic, respectively): 5 minutes: 9.16 ± 0.15 and 3.21 ± 0.38; 10 minutes: 8.81 ± 0.19 and 3.62 ± 0.37; 15 minutes: 8.75 ± 0.12 and 3.69 ± 0.31; and 20 minutes: 8.66 ± 0.22 and 3.95 ± 0.26; P < .00001. The half life of the vector was 2.66 ± 0.24 minutes. PK model data revealed that only 0.61 ± 0.43% of the original dose remained in the blood after delivery, and complete clearance from the system was achieved at 1 week. A PK transfer function revealed a positive correlation between exposure and in vivo transduction. Robust βARKct expression was found in all cardiac regions with none in the liver. CONCLUSION: MCARD may offer a viable method to establish a relationship between vector exposure and in vivo transduction. Using this methodology, it may be possible to address a critical need for establishing an effective therapeutic window. Published by Elsevier Inc.
Authors: J P Greelish; L T Su; E B Lankford; J M Burkman; H Chen; S K Konig; I M Mercier; P R Desjardins; M A Mitchell; X G Zheng; J Leferovich; G P Gao; R J Balice-Gordon; J M Wilson; H H Stedman Journal: Nat Med Date: 1999-04 Impact factor: 53.440
Authors: P Michael Grossman; Zhenguo Han; Maria Palasis; James J Barry; Robert J Lederman Journal: Catheter Cardiovasc Interv Date: 2002-03 Impact factor: 2.692
Authors: Philip Raake; Georges von Degenfeld; Rabea Hinkel; Robert Vachenauer; Torleif Sandner; Sabrina Beller; Martin Andrees; Christian Kupatt; Gerhard Schuler; Peter Boekstegers Journal: J Am Coll Cardiol Date: 2004-09-01 Impact factor: 24.094
Authors: Charles R Bridges; Kapil Gopal; David E Holt; Charles Yarnall; Steven Cole; Rochelle B Anderson; Xiaoqing Yin; Anthony Nelson; Benjamin W Kozyak; Zhonglin Wang; James Lesniewski; Leonard T Su; Danielle M Thesier; Hari Sundar; Hansell H Stedman Journal: J Thorac Cardiovasc Surg Date: 2005-11 Impact factor: 5.209
Authors: J D White; D M Thesier; J B D Swain; M G Katz; C Tomasulo; A Henderson; L Wang; C Yarnall; A Fargnoli; M Sumaroka; A Isidro; M Petrov; D Holt; R Nolen-Walston; W J Koch; H H Stedman; J Rabinowitz; C R Bridges Journal: Gene Ther Date: 2011-01-13 Impact factor: 5.250
Authors: P Boekstegers; G von Degenfeld; W Giehrl; D Heinrich; R Hullin; C Kupatt; G Steinbeck; G Baretton; G Middeler; H Katus; W M Franz Journal: Gene Ther Date: 2000-02 Impact factor: 5.250
Authors: M G Kaplitt; X Xiao; R J Samulski; J Li; K Ojamaa; I L Klein; H Makimura; M J Kaplitt; R K Strumpf; E B Diethrich Journal: Ann Thorac Surg Date: 1996-12 Impact factor: 4.330
Authors: Leigh K Hawkins; J Erik Mylroie; Dafne A Oliveira; J Spencer Smith; Seval Ozkan; Gary L Windham; W Paul Williams; Marilyn L Warburton Journal: PLoS One Date: 2015-06-19 Impact factor: 3.240